Literature DB >> 20967191

Immunophenotypic diagnosis of primary cutaneous lymphomas: a review for the practicing dermatologist.

Shannon M Campbell, Sara B Peters, Matthew J Zirwas, Henry K Wong.   

Abstract

The application of CD markers to medicine has advanced our understanding of several dermatological diseases, most notably primary cutaneous lymphomas. CD markers are monoclonal antibodies that target cell surface molecules on leukocytes and antigens from other cells. T-cell processes are typically CD3+, CD20-, CD45+ while B-cell processes are typically CD3-, CD20+, and CD45+. Other CD markers are used to further delineate cutaneous lymphomas. Although an imperfect system, CD markers empower dermatologists to synthesize immunophenotyping with clinical findings and formulate an appropriate diagnosis.

Entities:  

Year:  2010        PMID: 20967191      PMCID: PMC2958192     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  9 in total

Review 1.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.

Authors:  Eric C Vonderheid; Maria Grazia Bernengo; Günter Burg; Madeleine Duvic; Peter Heald; Liliane Laroche; Elise Olsen; Mark Pittelkow; Robin Russell-Jones; Masahiro Takigawa; Rein Willemze
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

Review 2.  Unmasking antigens for immunohistochemistry.

Authors:  N MacIntyre
Journal:  Br J Biomed Sci       Date:  2001       Impact factor: 3.829

Review 3.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.

Authors:  R Willemze; H Kerl; W Sterry; E Berti; L Cerroni; S Chimenti; J L Diaz-Peréz; M L Geerts; M Goos; R Knobler; E Ralfkiaer; M Santucci; N Smith; J Wechsler; W A van Vloten; C J Meijer
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

Review 4.  Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry.

Authors:  Jean-Marc Fritschy
Journal:  Eur J Neurosci       Date:  2008-12       Impact factor: 3.386

5.  The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease.

Authors:  Peter Ellmark; Adrian Woolfson; Larissa Belov; Richard I Christopherson
Journal:  Methods Mol Biol       Date:  2008

6.  Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients.

Authors:  Kazuo Kodama; Cesare Massone; Andreas Chott; Dieter Metze; Helmut Kerl; Lorenzo Cerroni
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

7.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

Authors:  T Miyashita; J C Reed
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

8.  Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas.

Authors:  B W Baron; G Nucifora; N McCabe; R Espinosa; M M Le Beau; T W McKeithan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  CD molecules 2005: human cell differentiation molecules.

Authors:  Heddy Zola; Bernadette Swart; Ian Nicholson; Bent Aasted; Armand Bensussan; Laurence Boumsell; Chris Buckley; Georgina Clark; Karel Drbal; Pablo Engel; Derek Hart; Václav Horejsí; Clare Isacke; Peter Macardle; Fabio Malavasi; David Mason; Daniel Olive; Armin Saalmueller; Stuart F Schlossman; Reinhard Schwartz-Albiez; Paul Simmons; Thomas F Tedder; Mariagrazia Uguccioni; Hilary Warren
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

  9 in total
  2 in total

1.  Rare case of T-cell lymphoma presenting as acute myelopathy.

Authors:  Verena Clarissa Samara; Adam de Havenon
Journal:  BMJ Case Rep       Date:  2016-10-21

Review 2.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.